Dr Reddy’s Laboratories has acquired the trademarks of specialty brands Progynova and Cyclo-Progynova and related assets for India from UK-headquartered Mercury Pharma Group.
The acquisition strengthens the gynecology portfolio and marks an entry into the hormone replacement therapy (HRT) segment, Dr Reddy said on Wednesday.
Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of symptoms of estrogen deficiency and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of symptoms of estrogen deficiency, providing estrogen and progestin components.
Progynova is the number one brand in the estradiol-represented pharmaceutical market, with strong physician equity and brand recall in India. The brand registered sales of Rs 100 crore, the Hyderabad-based pharmaceutical company said, citing IQVIA MAT figures for December 2025.
“The acquisition will spearhead our expansion in the HRT segment, strengthening our existing gynecology portfolio in India,” said MV Ramana, CEO, Branded Markets (India and Emerging Markets).
Published – 18 February 2026 at 10:15 PM IST
